Relmada Therapeutics Announces Publication of REL1017 Phase 1 Studies Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/3/2026

1. SNOW
2. AVGO
3. RARE
4. HPE
5. FIVE
6. SPY
7. VRTS
8. NTAP
9. OLLI
10. NTSK

Go back to Relmada Therapeutics Announces Publication of REL1017 Phase 1 Studies Results
(NASDAQ: RLMD) Delayed: 4.37 -0.17 (3.74%)
Previous Close $4.54    52 Week High $4.10 
Open $4.55    52 Week Low $0.87 
Day High $4.58    P/E N/A 
Day Low $4.33    EPS $0.00 
Volume 847,510